New drug cocktail aims to shrink kidney tumors before surgery
NCT ID NCT07389629
First seen Feb 05, 2026 · Last updated Jun 20, 2026 · Updated 20 times
Summary
This phase 2 trial is testing whether a combination of two immunotherapy drugs (QL1706) and a targeted therapy (lenvatinib) can shrink kidney tumors before surgery. The goal is to make partial nephrectomy (removing only the tumor) possible for patients whose tumors are currently too complex to operate on safely. About 25 adults with clear cell renal cell carcinoma will receive the drugs for 2 to 4 cycles before surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, 0755, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QL1706 (iparomlimab and tuvonralimab) plus lenvatinib
What this could lead to
If successful, this combination could shrink kidney tumors enough to allow safer, kidney-sparing surgery instead of full kidney removal.
What could go wrong
This is a small, early-phase trial with only 25 people, so results may not apply to everyone. The drug combination can cause side effects like high blood pressure, fatigue, or immune-related reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.